HOME >> BIOLOGY >> NEWS
Anticancer drug reveals alternate means of inducing cell suicide

Derivatives of the COX-2 inhibitor celecoxib can trigger cancer cell suicide, or apoptosis, but not necessarily through the recognized means of blocking COX-2 enzyme activity, a new study concludes. By separating COX-2 activity from apoptosis, researchers have a starting point for designing new classes of anticancer drugs, write Xueqin Song, Ching-Shih Chen, Ph.D., Ohio State University, and their coworkers in the April 17 issue of the Journal of the National Cancer Institute.

Celecoxib, an anti-inflammation pill for arthritis, is being studied for its potential in preventing and treating certain cancers. In a large percentage of tumors, the COX-2 enzyme is elevated, say Ernest T. Hawk, M.D., M.P.H., of the National Cancer Institute, and his coworkers in an accompanying editorial. They point out that past studies have shown that decreasing levels of COX-2 can suppress the growth of tumors. However, it has been unclear whether celecoxibs anticancer effects depend on COX-2 inhibition alone.

To find out, Chen and his coworkers created prostate cancer cells lacking the COX-2 enzyme. In contrast to the effects of COX-2 inhibitors such as celecoxib, which induce cell death, cells that lacked COX-2 remained alive. Exposure of these cells lacking COX-2 to various COX-2 inhibitors did lead to cell death. Whats more, derivatives of celecoxib that did not block COX-2 activity also caused cell death.

The authors note that these events were associated not with levels of COX-2 but with decreased phosphorylation of Akt and ERK2 proteins. This mode of action differs from that of conventional anticancer drugs, they point out.

In the accompanying editorial, Hawk and his colleagues note that celecoxib is being tested for the treatment and prevention of colon cancer and that newer generations of COX-2 inhibitors could prove to be safer and more effective.

However, they point out that the current findings are based on concentrations of c
'"/>

Contact: Linda Wang
jncinews@oup-usa.org
301-841-1287
Journal of the National Cancer Institute
16-Apr-2002


Page: 1 2

Related biology news :

1. Anticancer drug zebularine specifically targets tumor cells
2. The Bodys Anticancer Weaponry Backfires In Old Age
3. Enzymes "Magic" May Hold Key to Anticancer and Antimicrobial Drugs
4. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species
5. Brown research reveals key insight into memory-making
6. Study reveals why eyes in some paintings seem to follow viewers
7. New dye directly reveals activated proteins in living cells
8. Study reveals first genetic step necessary for prostate cancer growth
9. Study of flu patients reveals virus outsmarting key drug
10. Study in Science reveals recreational fishing takes big bite of ocean catch
11. Plumbing trees plumbing reveals their engineering skill

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anticancer drug reveals alternate means inducing cell suicide

(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
(Date:8/27/2015)... Aug. 27, 2015  Neogen Corporation (NASDAQ: NEOG ... of United Kingdom -based Lab M ... media and diagnostic systems. Lab M ... leading provider of microbial testing and diagnostic products for ... The company currently sells into more than 70 countries ...
(Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a commercial ... relationship of genetics and hypertension at the International Academy of Cardiology ... Columbia, Canada. The event, which boasts an extensive overview of the latest research ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
Cached News: